Sam Fazeli

Helios has significantly outperformed the HS Bio, the Hong Kong Hang Seng Bio Index, and is up 300% in the past 12 months versus the 70% for the index itself, which is quite a wonderful thing to see.

We will get to talk a little bit about the performance of the China biotech sector.

But without further ado, I want to welcome Xing Li to the podcast.

And maybe if I could ask you to just tell us a little bit about your own history.

What's your background?

What brought you to sit in the seat that I see you sitting in right now?

That's wonderful to hear.

I have to say, I think we're going to focus probably a lot more on oncology today, as Shingley knows that we have a very deep effort in oncology, but clearly your background in cardiometabolic

would also be a fantastic conversation to have whenever we get to that point, given all the interest and the sudden resurgence of interest in cardiometabolic, having been shunned by the world of pharma for a decade or two.

And now, of course, with the advent of GLP-1s and obesity.

And of course, GLP-1s also seem to have a role to play in preventing cancer.

Or one day, I'm sure, when we get some more data that's useful to talk about, we can talk about that.

So that's actually a really good segue to go and move into Fosun Pharma.

First on Pharma is, you know, I did say $5.7 billion of revenue in 2024.

I mean, a lot of that's coming from, I don't know what to call it, legacy business, legacy product or standard pharmaceutical products.

And then, of course, there's the innovative therapies that I think is what the company wants to be more focused on or as focused on going forward.

So do you want to give us a little bit of a breakdown of how the company businesses are structured in terms of segments, etc.

?

Now, so that's interesting.

I mean, I have a friend of mine who is a well-known immunologist who tells me that there isn't a single disease that you can point to that doesn't have the immune system involved in it.